Phase II study of 90Y ibritumomab tiuxetan (Zevalin) in patients with untreated follicular non-Hodgkin's lymphoma.
Phase of Trial: Phase II
Latest Information Update: 02 May 2016
At a glance
- Drugs Ibritumomab tiuxetan (Primary)
- Indications Follicular lymphoma
- Focus Adverse reactions; Biomarker; Therapeutic Use
- Acronyms ZEUS
- 13 Dec 2011 Results presented at the 53rd Annual Meeting and Exposition of the American Society of Hematology.
- 12 Dec 2011 Status changed from recruiting to active, no longer recruiting, as reported by the 53rd AMEASH
- 21 Jun 2011 New trial record